商洛市艾滋病抗病毒治疗病例生存率及影响因素分析

doi:10.19485/j.cnki.issn2096-5087.2020.01.005

Preventive Medicine

2020, Vol. 32

Issue (1): 18-21 DOI: 10.19485/j.cnki.issn2096-5087.2020.01.005

Orginal Article

Current Issue | Archive | Adv Search

Survival rate and its influencing factors of HIV/AIDS with antiretroviral therapy in Shangluo

YANG Xiaodan^*, TIAN Chunyan, LI Yueyou, MAO Zhaoming, JIA Wentao

^*Shangluo Center for Disease Control and Prevention,Shangluo,Shaanxi 726000,China

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (442 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the survival status and influencing factors of HIV/AIDS patients after receiving highly active antiretroviral therapy（HAART）in Shangluo,Shaanxi Province,so as to provide evidence for improving the effect of HAART. Methods HIV/AIDS patients who received HAART for the first time in Shangluo from 2010 to 2018 were investigated. Life table method was used to analyze the survival rate,mortality rate and median survival time of the subjects. A proportional hazards model was used to analyze the influencing factors for the survival time of HIV/AIDS patients. Results A total of 286 HIV/AIDS patients were collected,and 27 of them died of AIDS. After HAART,the 1-year,cumulative survival rates of less than 1 year,4 years and 8 years were 93.95%,89.71% and 88.39%,respectively. The results of multivariate proportional hazards regression analysis showed that the patients aged 30 years when first received HAART had higher risk of death than those aged 18-29 years（RR：4.208-24.095,95%CI：1.219-79.491）;patients with AIDS had higher risk of death than those with HIV（RR=38.590, 95%CI：15.451-96.382）;patients by homosexual transmission（RR=3.425,95%CI：1.385-8.470）and non-sexual transmission（RR=10.299,95%CI：3.602-29.446）had higher risk of death than those by heterosexual transmission;patients with baseline CD4⁺T lymphocytes number of 200/μL and more（RR：0.133-0.170,95%CI：0.048-0.604）had lower risk of death than those with less than 200/μL. Conclusions The survival rate of HIV/AIDS patients in Shangluo after receiving HAART is relatively high. Age at the start of treatment,course of disease,route of infection and the number of CD4⁺T lymphocytes at baseline are the influencing factors of survival time.

Key words： HIV/AIDS highly active antiretroviral therapy survival analysis influencing factors

Received: 01 July 2019 Revised: 10 September 2019 Published: 10 January 2020

ZTFLH:

R512.97

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Xiaodan
	TIAN Chunyan
	LI Yueyou
	MAO Zhaoming
	JIA Wentao

Cite this article:

YANG Xiaodan,TIAN Chunyan,LI Yueyou, et al. Survival rate and its influencing factors of HIV/AIDS with antiretroviral therapy in Shangluo[J]. Preventive Medicine, 2020, 32(1): 18-21.

URL:

http://www.zjyfyxzz.com/EN/10.19485/j.cnki.issn2096-5087.2020.01.005 OR http://www.zjyfyxzz.com/EN/Y2020/V32/I1/18

[1] 中国疾病预防控制中心. 国家卫生健康委员会2018年11月23日例行新闻发布会散发材料之一:我国艾滋病防治工作进展. 中国疾病预防控制中心性病艾滋病预防控制中心[Z].(2018- 11-23)[2019-09-10]. http://ncaids.chinacdc.cn/xxgx/yqxx/ 201811 /t20181123_ 197488.htm.
[2] 梁道斌,秦小超,黄锐洁,等. 高效抗反转录病毒治疗HIV/AIDS患者的生存时间及其影响因素分析[J]. 广西医学,2017,39(2):228-233.
[3] 于兰,惠珊,李婷,等. 黑龙江省2004—2018年首次接受艾滋病免费抗病毒治疗患者流行病学特征[J]. 中国公共卫生管理,2019,35(3):375-377.
[4] 马龙,胡改霞,蔺淞锋,等. 陕西省铜川市HIV/AIDS生存时间及影响因素[J]. 中国热带医学,2019,19(6):556-559.
[5] 陈昭云,孙燕,赵清霞,等. 河南省抗病毒治疗不同时期HIV/AIDS病人生存状况比较分析[J]. 中国艾滋病性病,2018, 24(12):24-28.
[6] 董丽芳,王敬军,常文辉,等. 陕西省HIV/AIDS患者生存时间回顾性队列研究[J]. 中国卫生统计,2014,31(2):213-215.
[7] 王莹莹,杨海涛,王永红,等. 石家庄市358例艾滋病患者抗逆转录病毒治疗后生存分析及危险因素研究[J]. 中华疾病控制杂志,2018,22(3):258-261.
[8] 赵艳秋,崔朋伟,傅卓华,等.苏州市2005—2015年艾滋病抗病毒治疗患者生存分析[J]. 江苏预防医学,2017,28(3):277-279.
[9] 崔倩,俞文祥,祁耀,等. 盐城市2005—2015年艾滋病抗病毒治疗患者生存分析[J]. 实用预防医学,2018,25(5):538-542.
[10] 张燕,何晓茜,廖清华,等. 2009—2018年深圳市新报告50岁及以上HIV/AIDS病例流行特征分析[J]. 预防医学,2019,31(9):911-913.
[11] HUANG P,TAN J,MA W,et al.Outcomes of antiretroviral treatment in HIV-infected adults:a dynamic and observational cohort study in Shenzhen,China,2003-2014[J]. BMJ Open,2015,5(5):e007508.
[12] CARRIQUIRY G,FINK V,ROBERT K J,et al.Mortality and loss to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the Caribbean[J]. J Int AIDS Soc,2015,18(1):20016.
[13] 王云霞,张曼,李翔,等. 乌鲁木齐市4 445例艾滋病患者抗病毒治疗后生存分析[J]. 现代预防医学,2015,42(8):1512-1515.
[14] 张梦妍,胡婷,任强,等. 陕西省不同社会人口学特征的男男性行为者5年HIV新发感染率监测分析[J]. 中国卫生检验杂志,2017,27(13):111-113.
[15] 宁铁林,郑敏娜,柏建芸,等. 2010—2015年天津市男男同性性行为者HIV-1新近感染状况调查[J]. 中国病毒病杂志,2019,9(2):91-95.
[16] 傅卓华,赵艳秋,赵秀萍,等. 苏州市男男性行为人群艾滋病抗病毒治疗疗效分析[J]. 上海预防医学,2015,27(12):741-744.
[17] 江洪波,林铠浩,黎静,等. 广州市年轻男男性行为人群艾滋病相关知识知晓情况及其影响因素分析[J]. 国际病毒学杂志,2019,26(3):160-164.
[18] 陈婉君,阮建军,朱碧香,等. 男男性行为人群HIV感染状态知情交友调查[J]. 预防医学,2019,31(1):1-4.
[19] 陈鹏,李丰,朱三梅,等. 湖南省株洲市2008—2018年报告的老年HIV/AIDS病例流行特征[J]. 中国热带医学,2019,19(9):868-871,880.
[20] 薛建,程晓松,林荣,等. 烟台市HIV/AIDS病例生命质量及影响因素分析[J]. 预防医学,2019,31(5):493-498.
[21] 肖智毅,邢彦,王雪梅. 北京市海淀区632例艾滋病病毒感染者生存时间及影响因素研究[J]. 中国卫生检验杂志,2017,12(24):3627-3629.